Organisation paid for research Program year 2025 Source: CMS Open Payments

Wake Research Associ

Neither a doctor nor a teaching hospital

Research payments

$538,433

43 payments

Through program year 2025, Wake Research Associ is reported as receiving $538,433 in research payments, across 43 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$18,447	5
2024	Research	$4,958	5
2023	Research	$56,829	8
2022	Research	$35,932	5
2021	Research	$208,999	14
2020	Research	$195,363	4
2019	Research	$17,905	2

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $538,433 43 payments

Studies the money was for Research payments · program years 2019–2025

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata $216,556 9 payments
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $140,756 3 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $102,061 6 payments
A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata $28,330 3 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $24,593 2 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Had A Prior Atherosclerotic Cardiovascular Event Or Are at Risk for A First Atherosclerotic Cardiovascular Event – Move-Lp(A) $13,274 2 payments
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis $6,200 2 payments
A Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $2,539 1 payment
Pediatric Options for Migraine Relief A Randomized, Double Blind, Placebo Controlled Study of Lasmiditan for Acute Treatment of Migraine Pioneer Peds1 $2,279 5 payments
Pediatric Options for Migraine Relief A Randomized Double Blind Placebo Controlled Study of Lasmiditan for Acute Treatment of Migraine Pioneer Peds1 $1,064 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.